Background:The emergence of Coronavirus SARS-CoV-2 evoked an unprecedented threat *** since the spread of this pandemic research and clinical trials have concentrated on the repurposing of already exciting FDA drugs t...
详细信息
Background:The emergence of Coronavirus SARS-CoV-2 evoked an unprecedented threat *** since the spread of this pandemic research and clinical trials have concentrated on the repurposing of already exciting FDA drugs to find a successful candidate to combat ***:The objective of this study is to propose a therapeutic protocol that may have a potential solution to treat the severe infections associated with *** clinical application of this protocol(Al-Akidi Therapeutic Protocol,A-TP)is highly recommended,as there are several scientific evidences that support this trusted protocol to be of great *** and Materials:This A-TP includes the use of one of the respiratory Fluoroquinolones(Levofloxacin or moxifloxacin)in doses of 500 mg twice daily for 7-10 days,together with high doses of Vitamin D3(10000 IU/day)and Zinc(50 mg daily)for few *** protocol is based on the previous antiviral activity of those Fluoroquinolones towards few viruses,the potent antibacterial activity on respiratory infections and high available concentrations in the *** is also based on molecular docking of Levofloxacin and moxifloxacin on various viral ***:Molecular docking showed encouraging and very interesting docking scores and binding affinity of Levofloxacin and moxifloxacin to certain viral enzymes,such as,RNA dependent RNA polymerase(RdRp),3-Cysteine-Like protease,Neuraminidase,Replicase polyproteins and Trans-Membrane Protease Serine 2 inhibitor(TMPRSS2).The highly expected clinical results of using this protocol are:reduce infection,control of temperature,improve breathing with less dependent on supplemented oxygen,and remarkable reduction of the pro-inflammatory cytokine storm,and hence,reduce hospitalization and ***:Levofloxacin is highly recommended in managing the severe infections associated with Corona virus and has a remarkable reduction of pro-inflammatory cytokine storm as an immuomodulating
Third generation of quinolones,such as levofloxacin and moxifloxacin,-containing regimens are often used in second-line or rescue treatment of Helicobacter pylori ***,the increasing antibiotic resistance to quinolones...
详细信息
Third generation of quinolones,such as levofloxacin and moxifloxacin,-containing regimens are often used in second-line or rescue treatment of Helicobacter pylori ***,the increasing antibiotic resistance to quinolones affects the efficacies of quinolones-containing therapies in recent ***,there is a need to enhance the effectiveness of quinolonescontaining ***,a fourth-generation quinolone,and vonoprazan,a novel potassium-competitive acid blocker,are now available as more effective treatment *** aim of this paper is to summarize the current evidence of quinolone-containing therapies in rescue treatments,and to discuss the importance of drug sensitivity tests or analysis of gyrA mutation before treatments.
先灵葆雅公司(Schering—Plough Corporation)于2006年7月28日报道,单独使用Avelox(盐酸莫西沙星,moxifloxacin HCl)治疗复杂性腹腔内感染(cIAI)与标准的多次给药抗生素联用的治疗效果和耐受性相当。该结论来自一个有681位受试患者参与的研究结果(近期发表于Annals of Surgery)。Avelox是由美国FDA批准上市的可单独使用治疗由多种微生物引起。IAI的唯一氟喹诺酮类抗生素,可有效根除包括大肠埃希菌和脆弱拟杆菌在内的常见细菌。
暂无评论